Statins — HMG-CoA reductase inhibitors reducing LDL-C by 30–50% — have saved millions of lives since the 4S trial in 1994 established statin therapy as the cornerstone of cardiovascular prevention. Yet even at maximally tolerated statin doses, the Cholesterol Treatment Trialists' collaborative found residual cardiovascular risk of 60–70% compared to non-CV-event populations — meaning the majority of cardiovascular events in statin-treated patients remain unaddressed by LDL reduction alone. The post-statin era of cardiovascular prevention addresses this residual risk through multiple mechanisms: aggressive LDL reduction beyond statin capacity, triglyceride reduction, inflammation reduction, and risk factor management in populations previously underserved by statin-centric approaches. Healthcare facilities treating cardiovascular patients require appropriate monitoring supplies from our diagnostic equipment section and lab supplies catalog.
PCSK9 Inhibitors: LDL to Target
Evolocumab (Repatha) and alirocumab (Praluent) — monoclonal antibodies inhibiting PCSK9 (the hepatocyte surface receptor recycling regulator) — reduce LDL-C by 50–65% on top of maximally tolerated statin therapy. FOURIER (evolocumab) and ODYSSEY Outcomes (alirocumab) trials demonstrated significant cardiovascular event reduction in high-risk secondary prevention patients, with LDL-C reductions to 30–40 mg/dL range. The landmark cost-effectiveness barriers have been substantially addressed through price reductions since 2017: evolocumab and alirocumab are now accessible for high-risk patients who fail to achieve LDL targets on statin + ezetimibe. Inclisiran (Leqvio) — an siRNA PCSK9 inhibitor requiring only biannual dosing — has added a compelling adherence advantage for patients with high risk of statin non-adherence.
Inflammation: The Residual Risk Target
The CANTOS trial (canakinumab targeting IL-1β) confirmed the inflammation hypothesis of atherosclerosis — reducing cardiovascular events independently of lipid changes in patients with elevated hsCRP. Colchicine 0.5mg daily (COLCOT and LoDoCo2 trials) reduces major adverse cardiovascular events by 23% in post-ACS and stable coronary artery disease patients — at a fraction of biologic therapy cost. ACC/AHA 2023 guidelines now include low-dose colchicine as a Class IIa recommendation for high-risk secondary prevention patients. CRP, IL-6, and hsCRP monitoring are increasingly incorporated into cardiovascular risk assessment panels — laboratory supplies supporting these tests are available through our lab section.
